On November 30th, we hosted a discussion with Dr. Bruce Quinn on reimbursement prospects for early cancer detection testing.  Bruce is the go-to expert on all things reimbursement for the Diagnostics industry. He specializes in Medicare policy, and helps both large and small companies understand and overcome hurdles to commercialization. Bruce is the Principal at Bruce Quinn Associates, and previously served as a Policy & Strategy Expert at Foley Hoag. Prior to that, he served as the Medical Director for California’s Medicare Program

Our discussion focused on diagnostics for early cancer detection. There are a number of liquid biopsy entrants developing new tools for early detection.  Our discussion focused on potential reimbursement pathways for Medicare, and steps needed to potentially earn coverage. Companies in focus from our coverage include Illumina (ILMN), Myriad Genetics (MYGN), and non-covered Exact Sciences (EXAS), Guardant Health (GH), and private companies Freenome and Thrive.